238 related articles for article (PubMed ID: 31254645)
1. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
2. PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors.
Negrete M; Romero-Ben E; Gutiérrez-Valencia A; Rosales-Barrios C; Alés E; Mena-Barragán T; Flores JA; Castillejos MC; de la Cruz-Ojeda P; Navarro-Villarán E; Cepeda-Franco C; Khiar N; Muntané J
ACS Appl Bio Mater; 2021 Jun; 4(6):4789-4799. PubMed ID: 35007028
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
4. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
[No Abstract] [Full Text] [Related]
5. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
Varshosaz J; Raghami F; Rostami M; Jahanian A
J Liposome Res; 2019 Dec; 29(4):383-398. PubMed ID: 30668221
[TBL] [Abstract][Full Text] [Related]
6. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
7. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
8. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
9. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
Cai M; Li B; Lin L; Huang J; An Y; Huang W; Zhou Z; Wang Y; Shuai X; Zhu K
Biomater Sci; 2020 Jun; 8(12):3485-3499. PubMed ID: 32432234
[TBL] [Abstract][Full Text] [Related]
10. Curcumin-loaded galactosylated BSA nanoparticles as targeted drug delivery carriers inhibit hepatocellular carcinoma cell proliferation and migration.
Huang Y; Hu L; Huang S; Xu W; Wan J; Wang D; Zheng G; Xia Z
Int J Nanomedicine; 2018; 13():8309-8323. PubMed ID: 30584302
[TBL] [Abstract][Full Text] [Related]
11. Galactosylated TPGS Micelles for Docetaxel Targeting to Hepatic Carcinoma: Development, Characterization, and Biodistribution Study.
Tekchandani P; Kurmi BD; Paliwal R; Paliwal SR
AAPS PharmSciTech; 2020 Jun; 21(5):174. PubMed ID: 32548786
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
Su Y; Wang K; Li Y; Song W; Xin Y; Zhao W; Tian J; Ren L; Lu L
Nanomedicine (Lond); 2018 May; 13(9):1009-1023. PubMed ID: 29630448
[TBL] [Abstract][Full Text] [Related]
13. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
[TBL] [Abstract][Full Text] [Related]
14. pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
Zhang W; Cai J; Wu B; Shen Z
J Biomater Appl; 2019 Aug; 34(2):219-228. PubMed ID: 31084233
[No Abstract] [Full Text] [Related]
15. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma.
Li Z; Ye L; Liu J; Lian D; Li X
Int J Nanomedicine; 2020; 15():1469-1480. PubMed ID: 32184599
[TBL] [Abstract][Full Text] [Related]
17. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
19. Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Grillone A; Riva ER; Mondini A; Forte C; Calucci L; Innocenti C; de Julian Fernandez C; Cappello V; Gemmi M; Moscato S; Ronca F; Sacco R; Mattoli V; Ciofani G
Adv Healthc Mater; 2015 Aug; 4(11):1681-90. PubMed ID: 26039933
[TBL] [Abstract][Full Text] [Related]
20. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
